Association between vitamin D insufficiency and tuberculosis in a vietnamese population

Ho‐Pham, Lan T.; Nguyen, Nguyen D.; Nguyen, Tong T; Nguyen, Dung Huu; Bui, Phuong K; Nguyen, Vien N; Nguyen, Tuan Van

doi:10.1186/1471-2334-10-306

Cited by 69 publications

(69 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study in Vietnam found that 'The prevalence of vitamin D insufficiency was 35.4% in men with TB and 19.5% in controls (P ¼ 0.01). In women, there were no significant differences in serum 25(OH)D and serum (parathyroid hormone) levels between TB patients and controls' (Ho-Pham et al, 2010).…”

Section: Cardiovascular Diseasementioning

confidence: 93%

An estimate of the global reduction in mortality rates through doubling vitamin D levels

Grant

2011

Eur J Clin Nutr

View full text Add to dashboard Cite

Background/Objectives: The goal of this work is to estimate the reduction in mortality rates for six geopolitical regions of the world under the assumption that serum 25-hydroxyvitamin D (25(OH)D) levels increase from 54 to 110 nmol/l. Subjects/Methods: This study is based on interpretation of the journal literature relating to the effects of solar ultraviolet-B (UVB) and vitamin D in reducing the risk of disease and estimates of the serum 25(OH)D level-disease risk relations for cancer, cardiovascular disease (CVD) and respiratory infections. The vitamin D-sensitive diseases that account for more than half of global mortality rates are CVD, cancer, respiratory infections, respiratory diseases, tuberculosis and diabetes mellitus. Additional vitamin D-sensitive diseases and conditions that account for 2 to 3% of global mortality rates are Alzheimer's disease, falls, meningitis, Parkinson's disease, maternal sepsis, maternal hypertension (pre-eclampsia) and multiple sclerosis. Increasing serum 25(OH)D levels from 54 to 110 nmol/l would reduce the vitamin D-sensitive disease mortality rate by an estimated 20%. Results: The reduction in all-cause mortality rates range from 7.6% for African females to 17.3% for European females. Reductions for males average 0.6% lower than for females. The estimated increase in life expectancy is 2 years for all six regions. Conclusions: Increasing serum 25(OH)D levels is the most cost-effective way to reduce global mortality rates, as the cost of vitamin D is very low and there are few adverse effects from oral intake and/or frequent moderate UVB irradiance with sufficient body surface area exposed.

show abstract

Section: Cardiovascular Diseasementioning

confidence: 93%

An estimate of the global reduction in mortality rates through doubling vitamin D levels

Grant

2011

Eur J Clin Nutr

View full text Add to dashboard Cite

show abstract

“…Since then, eleven case-control studies investigating the association between vitamin D status and susceptibility to active TB have been published. Of these, seven have reported a statistically significant association between vitamin D deficiency and susceptibility to active TB (34)(35)(36)(37)(38)(39)(40) , three have reported a non-statistically significant trend towards such an association (41)(42)(43) and one (44) has reported that active TB was associated with both 'high' and 'low' serum 25(OH)D concentrations (> 140 and < 75 nmol/l, respectively). Potential explanations for an association between vitamin D deficiency and active TB include both causality (i.e.…”

Section: Association Between Vitamin D Deficiency and Susceptibility mentioning

confidence: 99%

Old wine in new bottles: vitamin D in the treatment and prevention of tuberculosis

Martineau

2011

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Tuberculosis (TB) is a major cause of mortality, responsible for 1 . 68 million deaths worldwide in 2009. The global prevalence of latent Mycobacterium tuberculosis infection is estimated to be 32 %, and this carries a 5-20% lifetime risk of reactivation disease. The emergence of drug-resistant organisms necessitates the development of new agents to enhance the response to antimicrobial therapy for active TB. Vitamin D was used to treat TB in the pre-antibiotic era, and its active metabolite, 1,25-dihydoxyvitamin D, has long been known to enhance the immune response to mycobacteria in vitro. Vitamin D deficiency is common in patients with active TB, and several clinical trials have evaluated the role of adjunctive vitamin D supplementation in its treatment. Results of these studies are conflicting, reflecting variation between studies in baseline vitamin D status of participants, dosing regimens and outcome measures. Vitamin D deficiency is also recognised to be highly prevalent among people with latent M. tuberculosis infection in both high-and low-burden settings, and there is a wealth of observational epidemiological evidence linking vitamin D deficiency with increased risk of reactivation disease. Randomised controlled trials of vitamin D supplementation for the prevention of active TB have yet to be performed, however. The conduct of such trials is a research priority, given the safety and low cost of vitamin D supplementation, and the potentially huge public health consequences of positive results. Tuberculosis: Vitamin D: Immunomodulation: Clinical trialsTuberculosis (TB) is a major public health problem. The global prevalence of latent Mycobacterium tuberculosis (MTB) infection has been estimated at 32% (1) , and this carries a 5-20% lifetime risk of reactivation disease in people who are not infected with HIV (2) ; reactivation rates higher than 10% per annum have been reported in HIVinfected people (3) . The WHO estimates that in 2009 there were 9 . 4 million incident cases of active TB, 14 million prevalent cases of TB, 1 . 3 million deaths from TB in HIV-uninfected people and 0 . 38 million deaths from TB in HIV-infected people (4) . The development of new agents to prevent acquisition or reactivation of latent MTB infection and to allow shortening of antimicrobial therapy regimens for active TB without loss of efficacy is a research priority. This paper reviews the growing body of evidence from studies conducted both in vitro and in vivo suggesting that vitamin D might have a role in the prevention and treatment of TB.

show abstract

“…It was reinforced in a recent case-control study involving 166 Vietnamese TB patients confirming the association between vitamin D deficiency and TB in man (p= 0.01) (50). Previous investigations have found that 25-hydroxycholecalciferol (serum vitamin D) deficiency or absence was associated with active TB and an association was detected between the combination of VDR genotypes and 25-hydroxycholecalciferol deficiencies with TB development (51).…”

Section: Discussionmentioning

confidence: 78%

Unique CYP3A4 genetic variant in Brazilian tuberculosis patients with/without HIV

et al. 2011

View full text Add to dashboard Cite

Abstract. CYP3A4 is involved in tuberculosis (TB) and human immunodeficiency virus (HIV) drug metabolism. Transcriptional activation by rifampicin involves the CYP3A4 gene 5'-upstream region. Consequently, variation may interfere with transcription and enzymatic activity and even drug response. However, genetic polymorphisms and distribution of CYP3A4 allelic frequencies in individuals from Rio de Janeiro remain unknown. The aim of this study was to conduct research into sequencing the CYP3A4 5'-upstream region in Brazilian patients with and without HIV. This follow-up study involved 106 individuals undergoing treatment for TB and/ or HIV. The CYP3A4 5'-upstream region was analyzed using PCR, sequencing and clinical data. Male patients revealed a higher HIV frequency (p=0.021). The TB forms observed were pulmonary (48.1%), extrapulmonary (22.64%) and disseminated (27.36%). Lymph node form was the most frequent (70.83%) extrapulmonary form of TB. The only single nucleotide polymorphism detected in the population was c.-392A>G. Genotypes observed were CYP3A4*1A/CYP3A4*1A (45.3%), CYP3A4*1A/CYP3A4*1B (40.6%) and CYP3A4*1B/ CYP3A4*1B (14.2%), revealing a different distribution with extrapulmonary TB cases (17.6% CYP3A4*1A/CYP3A4*1B and 23.5% CYP3A4*1B/CYP3A4*1B). The CYP3A4*1A allele was found to be associated with tobacco use. The CYP3A4*1B mutant allele occurred in 34% of patients. This study revealed that the CYP3A4 5'-upstream regulatory region was highly conserved with the exception of the -392 position. Genotype association with tobacco suggests that CYP3A4 may participate in tobacco metabolism. Genotype distribution inversion in extrapulmonary TB cases suggests that CYP3A4 may be involved in TB prognosis.

show abstract

Association between vitamin D insufficiency and tuberculosis in a vietnamese population

Cited by 69 publications

References 24 publications

An estimate of the global reduction in mortality rates through doubling vitamin D levels

An estimate of the global reduction in mortality rates through doubling vitamin D levels

Old wine in new bottles: vitamin D in the treatment and prevention of tuberculosis

Unique CYP3A4 genetic variant in Brazilian tuberculosis patients with/without HIV

Contact Info

Product

Resources

About